On 1 June 2026, Xunfei Healthcare Technology Co., Ltd. (HKEX: 02506, “Xunfei Healthcare”) disclosed that it has completed a total capital contribution of RMB186.67 million to Anhui Heshuzhiyi Medical Technology Co., Ltd. (the “Target Company”), a joint venture established with Hefei Big Data Asset Operation Co., Ltd. (“Hefei Big Data”) for the construction of China’s National Pilot Base for Artificial Intelligence Application in primary healthcare.

Key Transaction Terms • Initial set-up: The Target Company was formed on 18 July 2024 with registered capital of RMB1.51 billion, owned 49% by Xunfei Healthcare and 51% by Hefei Big Data. • Capital restructuring: On 11 September 2025, the partners agreed to reduce registered capital to RMB200.00 million while keeping their stakes unchanged. They simultaneously committed a combined RMB368.72 million to meet construction funding needs—RMB180.67 million from Xunfei Healthcare and RMB188.05 million from Hefei Big Data. • Further capital injection: On 28 November 2025, an additional RMB12.24 million was paid in (RMB6.00 million by Xunfei Healthcare; RMB6.24 million by Hefei Big Data). • Cumulative outlay: Both parties have now contributed RMB380.97 million, of which Xunfei Healthcare’s share is RMB186.67 million. Amounts exceeding the subscribed capital are booked as capital reserve. No proceeds from Xunfei Healthcare’s IPO were used.

Project Funding Structure Total investment for the pilot base is budgeted at RMB608.00 million, comprising RMB243.20 million from state ultra-long-term special treasury bonds and RMB364.80 million in self-raised funds supplied by shareholder contributions.

Financial Snapshot of the Target Company • Net loss 2025: RMB9.56 million (unaudited). • Net asset value (31 Dec 2025): RMB365.17 million (unaudited).

Regulatory Status The capital contribution qualifies as a “discloseable transaction” under Chapter 14 of the Hong Kong Listing Rules (percentage ratio >5% but <25%). Xunfei Healthcare acknowledged that initial disclosure obligations were not met timely due to a misinterpretation that the injections were mere follow-ups to the 2024 JV formation. The company has outlined remedial measures, including enhanced Listing Rules training, strengthened internal reporting procedures, updated compliance checklists, and closer coordination with external advisers to prevent recurrence.

Strategic Rationale Participation in the only national-level AI medical pilot platform focused on primary care is expected to reinforce Xunfei Healthcare’s leadership in medical large-model AI, accelerate commercialization of its AI products in Hefei and Anhui Province, and enhance long-term competitive positioning and brand influence.

Hefei Big Data, the company’s 51% partner in the venture, is majority-owned by state-controlled entities under the Hefei Municipal SASAC and is classified as an independent third party to Xunfei Healthcare.